Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 177

1.

Optimizing the electronic medical record to improve patient care and conduct quality improvement initiatives in a concussion specialty clinic.

Simon KC, Reams N, Beltran E, Wang C, Hadsell B, Maurer D, Hillman L, Tideman S, Garduno L, Meyers S, Frigerio R, Maraganore DM.

Brain Inj. 2019 Oct 23:1-6. doi: 10.1080/02699052.2019.1680867. [Epub ahead of print]

PMID:
31644325
2.

Building of EMR Tools to Support Quality and Research in a Memory Disorders Clinic.

Simon KC, Yucus C, Castle J, Chesis R, Lai R, Hillman L, Tideman S, Garduno L, Meyers S, Frigerio R, Maraganore DM.

Front Neurol. 2019 Mar 7;10:161. doi: 10.3389/fneur.2019.00161. eCollection 2019.

3.

Using EHRs to advance epilepsy care.

Mbwana JS, Grinspan ZM, Bailey R, Berl M, Buchhalter J, Bumbut A, Danner Z, Glauser T, Glotstein A, Goodkin H, Jacobs B, Jones L, Kroner B, Lapham G, Loddenkemper T, Maraganore DM, Nordli D, Gaillard WD.

Neurol Clin Pract. 2019 Feb;9(1):83-88. doi: 10.1212/CPJ.0000000000000575.

PMID:
30859011
4.

Design and Implementation of Structured Clinical Documentation Support Tools for Treating Stroke Patients.

Simon KC, Munson R, Ong A, Gil FR, Campanella F, Hillman L, Lai R, Chesis R, Tideman S, Vazquez RM, Meyers S, Frigerio R, Maraganore D.

J Stroke Cerebrovasc Dis. 2019 May;28(5):1229-1235. doi: 10.1016/j.jstrokecerebrovasdis.2019.01.011. Epub 2019 Feb 6.

PMID:
30737069
5.

Sensitivity and Specificity of Diagnostic Criteria for Progressive Supranuclear Palsy.

Ali F, Martin PR, Botha H, Ahlskog JE, Bower JH, Masumoto JY, Maraganore D, Hassan A, Eggers S, Boeve BF, Knopman DS, Drubach D, Petersen RC, Dunkley ED, van Gerpen J, Uitti R, Whitwell JL, Dickson DW, Josephs KA.

Mov Disord. 2019 Aug;34(8):1144-1153. doi: 10.1002/mds.27619. Epub 2019 Feb 6.

6.

Successful utilization of the EMR in a multiple sclerosis clinic to support quality improvement and research initiatives at the point of care.

Claire Simon K, Hentati A, Rubin S, Franada T, Maurer D, Hillman L, Tideman S, Szela M, Meyers S, Frigerio R, Maraganore DM.

Mult Scler J Exp Transl Clin. 2018 Nov 30;4(4):2055217318813736. doi: 10.1177/2055217318813736. eCollection 2018 Oct-Dec.

7.

Design and implementation of pragmatic clinical trials using the electronic medical record and an adaptive design.

Simon KC, Tideman S, Hillman L, Lai R, Jathar R, Ji Y, Bergman-Bock S, Castle J, Franada T, Freedom T, Marcus R, Mark A, Meyers S, Rubin S, Semenov I, Yucus C, Pham A, Garduno L, Szela M, Frigerio R, Maraganore DM.

JAMIA Open. 2018 Jul;1(1):99-106. doi: 10.1093/jamiaopen/ooy017. Epub 2018 Jun 11.

8.

Long-term risk of depressive and anxiety symptoms after early bilateral oophorectomy.

Rocca WA, Grossardt BR, Geda YE, Gostout BS, Bower JH, Maraganore DM, de Andrade M, Melton LJ 3rd.

Menopause. 2018 Nov;25(11):1275-1285. doi: 10.1097/GME.0000000000001229.

PMID:
30358723
9.

Use of an Electronic Medical Record to Track Adherence to the Mediterranean Diet in a US Neurology Clinical Practice.

Rasmussen E, Fosnacht Morgan AM, Munson R, Ong A, Patel S, Yucus C, Pham A, Patel V, Frigerio R, Lai R, Hillman L, Tideman S, Wang C, Simon KC, Martínez-González MÁ, Maraganore DM.

Mayo Clin Proc Innov Qual Outcomes. 2018 Feb 1;2(1):49-59. doi: 10.1016/j.mayocpiqo.2017.12.003. eCollection 2018 Mar.

10.

Structured Clinical Documentation to Improve Quality and Support Practice-Based Research in Headache.

Meyers S, Claire Simon K, Bergman-Bock S, Campanella F, Marcus R, Mark A, Freedom T, Rubin S, Semenov I, Lai R, Hillman L, Tideman S, Pham A, Frigerio R, Maraganore DM.

Headache. 2018 Sep;58(8):1211-1218. doi: 10.1111/head.13348. Epub 2018 Aug 1.

PMID:
30066412
11.

Investigating ioflupane I123 injection and single photon emission tomography as an imaging biomarker for long-term sequelae following mild traumatic brain injury.

Reams N, Anderson J, Perlman R, Li W, Walters S, Tideman S, Wang C, Simon K, Frigerio R, Maraganore DM.

Brain Inj. 2018;32(1):105-112. doi: 10.1080/02699052.2017.1388443. Epub 2017 Nov 13.

PMID:
29131690
12.

From Brain Disease to Brain Health: Primary Prevention of Alzheimer's Disease and Related Disorders in a Health System Using an Electronic Medical Record-Based Approach.

Fosnacht AM, Patel S, Yucus C, Pham A, Rasmussen E, Frigerio R, Walters S, Maraganore D.

J Prev Alzheimers Dis. 2017;4(3):157-164. doi: 10.14283/jpad.2017.3.

13.

Structured clinical documentation in the electronic medical record to improve quality and to support practice-based research in epilepsy.

Narayanan J, Dobrin S, Choi J, Rubin S, Pham A, Patel V, Frigerio R, Maurer D, Gupta P, Link L, Walters S, Wang C, Ji Y, Maraganore DM.

Epilepsia. 2017 Jan;58(1):68-76. doi: 10.1111/epi.13607. Epub 2016 Nov 19.

14.

Evaluation of the interaction between LRRK2 and PARK16 loci in determining risk of Parkinson's disease: analysis of a large multicenter study.

Wang L, Heckman MG, Aasly JO, Annesi G, Bozi M, Chung SJ, Clarke C, Crosiers D, Eckstein G, Garraux G, Hadjigeorgiou GM, Hattori N, Jeon B, Kim YJ, Kubo M, Lesage S, Lin JJ, Lynch T, Lichtner P, Mellick GD, Mok V, Morrison KE, Quattrone A, Satake W, Silburn PA, Stefanis L, Stockton JD, Tan EK, Toda T, Brice A, Van Broeckhoven C, Uitti RJ, Wirdefeldt K, Wszolek Z, Xiromerisiou G, Maraganore DM, Gasser T, Krüger R, Farrer MJ, Ross OA, Sharma M; GEOPD Consortium.

Neurobiol Aging. 2017 Jan;49:217.e1-217.e4. doi: 10.1016/j.neurobiolaging.2016.09.022. Epub 2016 Oct 6.

15.

Genome-wide gene-environment interaction analysis of pesticide exposure and risk of Parkinson's disease.

Biernacka JM, Chung SJ, Armasu SM, Anderson KS, Lill CM, Bertram L, Ahlskog JE, Brighina L, Frigerio R, Maraganore DM.

Parkinsonism Relat Disord. 2016 Nov;32:25-30. doi: 10.1016/j.parkreldis.2016.08.002. Epub 2016 Aug 3.

16.

The clinical spectrum and natural history of pure akinesia with gait freezing.

Owens E, Josephs KA, Savica R, Hassan A, Klassen B, Bower J, Maraganore D, Matsumoto J, Ahlskog JE.

J Neurol. 2016 Dec;263(12):2419-2423. Epub 2016 Sep 13.

PMID:
27624121
17.

Low dose verapamil as an adjunct therapy for medically refractory epilepsy - An open label pilot study.

Narayanan J, Frech R, Walters S, Patel V, Frigerio R, Maraganore DM.

Epilepsy Res. 2016 Oct;126:197-200. doi: 10.1016/j.eplepsyres.2016.07.004. Epub 2016 Aug 4.

PMID:
27513375
18.

MAPT haplotype H1G is associated with increased risk of dementia with Lewy bodies.

Labbé C, Heckman MG, Lorenzo-Betancor O, Soto-Ortolaza AI, Walton RL, Murray ME, Allen M, Uitti RJ, Wszolek ZK, Smith GE, Kantarci K, Knopman DS, Lowe VJ, Jack CR Jr, Ertekin-Taner N, Hassan A, Savica R, Petersen RC, Parisi JE, Maraganore DM, Graff-Radford NR, Ferman TJ, Boeve BF, Dickson DW, Ross OA.

Alzheimers Dement. 2016 Dec;12(12):1297-1304. doi: 10.1016/j.jalz.2016.05.002. Epub 2016 Jun 7. Review.

19.

Quality improvement and practice-based research in neurology using the electronic medical record.

Maraganore DM, Frigerio R, Kazmi N, Meyers SL, Sefa M, Walters SA, Silverstein JC.

Neurol Clin Pract. 2015 Oct;5(5):419-429.

20.

Large-scale assessment of polyglutamine repeat expansions in Parkinson disease.

Wang L, Aasly JO, Annesi G, Bardien S, Bozi M, Brice A, Carr J, Chung SJ, Clarke C, Crosiers D, Deutschländer A, Eckstein G, Farrer MJ, Goldwurm S, Garraux G, Hadjigeorgiou GM, Hicks AA, Hattori N, Klein C, Jeon B, Kim YJ, Lesage S, Lin JJ, Lynch T, Lichtner P, Lang AE, Mok V, Jasinska-Myga B, Mellick GD, Morrison KE, Opala G, Pihlstrøm L, Pramstaller PP, Park SS, Quattrone A, Rogaeva E, Ross OA, Stefanis L, Stockton JD, Silburn PA, Theuns J, Tan EK, Tomiyama H, Toft M, Van Broeckhoven C, Uitti RJ, Wirdefeldt K, Wszolek Z, Xiromerisiou G, Yueh KC, Zhao Y, Gasser T, Maraganore DM, Krüger R, Sharma M; GEO-PD Consortium.

Neurology. 2015 Oct 13;85(15):1283-92. doi: 10.1212/WNL.0000000000002016. Epub 2015 Sep 9.

21.

Role for the microtubule-associated protein tau variant p.A152T in risk of α-synucleinopathies.

Labbé C, Ogaki K, Lorenzo-Betancor O, Soto-Ortolaza AI, Walton RL, Rayaprolu S, Fujioka S, Murray ME, Heckman MG, Puschmann A, McCarthy A, Lynch T, Siuda J, Opala G, Rudzinska M, Krygowska-Wajs A, Barcikowska M, Czyzewski K, Sanotsky Y, Rektorová I, McLean PJ, Rademakers R, Ertekin-Taner N, Hassan A, Ahlskog JE, Boeve BF, Petersen RC, Maraganore DM, Adler CH, Ferman TJ, Parisi JE, Graff-Radford NR, Uitti RJ, Wszolek ZK, Dickson DW, Ross OA.

Neurology. 2015 Nov 10;85(19):1680-6. doi: 10.1212/WNL.0000000000001946. Epub 2015 Sep 2. Erratum in: Neurology. 2015 Nov 10;85(19):1728.

22.

Clinically meaningful parameters of progression and long-term outcome of Parkinson disease: An international consensus statement.

Puschmann A, Brighina L, Markopoulou K, Aasly J, Chung SJ, Frigerio R, Hadjigeorgiou G, Kõks S, Krüger R, Siuda J, Wider C, Zesiewicz TA, Maraganore DM.

Parkinsonism Relat Disord. 2015 Jul;21(7):675-82. doi: 10.1016/j.parkreldis.2015.04.029. Epub 2015 May 1. Review.

PMID:
25952959
23.

Nicholas A. Vick, MD (1939–2014).

McMahon JP, Groothuis DR, Homer D, Maraganore DM.

Neurology. 2015 Feb 10;84(6):558-9. No abstract available.

PMID:
25811061
24.

Lack of replication of the GRIN2A-by-coffee interaction in Parkinson disease.

Ahmed I, Lee PC, Lill CM, Searles Nielsen S, Artaud F, Gallagher LG, Loriot MA, Mulot C, Nacfer M, Liu T, Biernacka JM, Armasu S, Anderson K, Farin FM, Lassen CF, Hansen J, Olsen JH, Bertram L, Maraganore DM, Checkoway H, Ritz B, Elbaz A.

PLoS Genet. 2014 Nov 20;10(11):e1004788. doi: 10.1371/journal.pgen.1004788. eCollection 2014 Nov. No abstract available.

25.

Global investigation and meta-analysis of the C9orf72 (G4C2)n repeat in Parkinson disease.

Theuns J, Verstraeten A, Sleegers K, Wauters E, Gijselinck I, Smolders S, Crosiers D, Corsmit E, Elinck E, Sharma M, Krüger R, Lesage S, Brice A, Chung SJ, Kim MJ, Kim YJ, Ross OA, Wszolek ZK, Rogaeva E, Xi Z, Lang AE, Klein C, Weissbach A, Mellick GD, Silburn PA, Hadjigeorgiou GM, Dardiotis E, Hattori N, Ogaki K, Tan EK, Zhao Y, Aasly J, Valente EM, Petrucci S, Annesi G, Quattrone A, Ferrarese C, Brighina L, Deutschländer A, Puschmann A, Nilsson C, Garraux G, LeDoux MS, Pfeiffer RF, Boczarska-Jedynak M, Opala G, Maraganore DM, Engelborghs S, De Deyn PP, Cras P, Cruts M, Van Broeckhoven C; GEO-PD Consortium.

Neurology. 2014 Nov 18;83(21):1906-13. doi: 10.1212/WNL.0000000000001012. Epub 2014 Oct 17.

26.

Does α-synuclein have a dual and opposing effect in preclinical vs. clinical Parkinson's disease?

Markopoulou K, Biernacka JM, Armasu SM, Anderson KJ, Ahlskog JE, Chase BA, Chung SJ, Cunningham JM, Farrer M, Frigerio R, Maraganore DM.

Parkinsonism Relat Disord. 2014 Jun;20(6):584-9; discussion 584. doi: 10.1016/j.parkreldis.2014.02.021. Epub 2014 Mar 5.

27.

Alpha-synuclein repeat variants and survival in Parkinson's disease.

Chung SJ, Biernacka JM, Armasu SM, Anderson K, Frigerio R, Aasly JO, Annesi G, Bentivoglio AR, Brighina L, Chartier-Harlin MC, Goldwurm S, Hadjigeorgiou G, Jasinska-Myga B, Jeon BS, Kim YJ, Krüger R, Lesage S, Markopoulou K, Mellick G, Morrison KE, Puschmann A, Tan EK, Crosiers D, Theuns J, Van Broeckhoven C, Wirdefeldt K, Wszolek ZK, Elbaz A, Maraganore DM; Genetic Epidemiology of Parkinson's Disease Consortium.

Mov Disord. 2014 Jul;29(8):1053-7. doi: 10.1002/mds.25841. Epub 2014 Feb 27.

28.

Protective effect of LRRK2 p.R1398H on risk of Parkinson's disease is independent of MAPT and SNCA variants.

Heckman MG, Elbaz A, Soto-Ortolaza AI, Serie DJ, Aasly JO, Annesi G, Auburger G, Bacon JA, Boczarska-Jedynak M, Bozi M, Brighina L, Chartier-Harlin MC, Dardiotis E, Destée A, Ferrarese C, Ferraris A, Fiske B, Gispert S, Hadjigeorgiou GM, Hattori N, Ioannidis JP, Jasinska-Myga B, Jeon BS, Kim YJ, Klein C, Kruger R, Kyratzi E, Lin CH, Lohmann K, Loriot MA, Lynch T, Mellick GD, Mutez E, Opala G, Park SS, Petrucci S, Quattrone A, Sharma M, Silburn PA, Sohn YH, Stefanis L, Tadic V, Tomiyama H, Uitti RJ, Valente EM, Vassilatis DK, Vilariño-Güell C, White LR, Wirdefeldt K, Wszolek ZK, Wu RM, Xiromerisiou G, Maraganore DM, Farrer MJ, Ross OA; Genetic Epidemiology Of Parkinson's Disease (GEO-PD) Consortium.

Neurobiol Aging. 2014 Jan;35(1):266.e5-14. doi: 10.1016/j.neurobiolaging.2013.07.013. Epub 2013 Aug 17.

29.

Population-specific frequencies for LRRK2 susceptibility variants in the Genetic Epidemiology of Parkinson's Disease (GEO-PD) Consortium.

Heckman MG, Soto-Ortolaza AI, Aasly JO, Abahuni N, Annesi G, Bacon JA, Bardien S, Bozi M, Brice A, Brighina L, Carr J, Chartier-Harlin MC, Dardiotis E, Dickson DW, Diehl NN, Elbaz A, Ferrarese C, Fiske B, Gibson JM, Gibson R, Hadjigeorgiou GM, Hattori N, Ioannidis JP, Boczarska-Jedynak M, Jasinska-Myga B, Jeon BS, Kim YJ, Klein C, Kruger R, Kyratzi E, Lesage S, Lin CH, Lynch T, Maraganore DM, Mellick GD, Mutez E, Nilsson C, Opala G, Park SS, Petrucci S, Puschmann A, Quattrone A, Sharma M, Silburn PA, Sohn YH, Stefanis L, Tadic V, Theuns J, Tomiyama H, Uitti RJ, Valente EM, Van Broeckhoven C, van de Loo S, Vassilatis DK, Vilariño-Güell C, White LR, Wirdefeldt K, Wszolek ZK, Wu RM, Hentati F, Farrer MJ, Ross OA; Genetic Epidemiology of Parkinson's Disease (GEO-PD) Consortium.

Mov Disord. 2013 Oct;28(12):1740-4. doi: 10.1002/mds.25600. Epub 2013 Aug 2.

30.

Genetic susceptibility loci, environmental exposures, and Parkinson's disease: a case-control study of gene-environment interactions.

Chung SJ, Armasu SM, Anderson KJ, Biernacka JM, Lesnick TG, Rider DN, Cunningham JM, Ahlskog JE, Frigerio R, Maraganore DM.

Parkinsonism Relat Disord. 2013 Jun;19(6):595-9. doi: 10.1016/j.parkreldis.2013.02.008. Epub 2013 Mar 16.

31.

A multi-centre clinico-genetic analysis of the VPS35 gene in Parkinson disease indicates reduced penetrance for disease-associated variants.

Sharma M, Ioannidis JP, Aasly JO, Annesi G, Brice A, Bertram L, Bozi M, Barcikowska M, Crosiers D, Clarke CE, Facheris MF, Farrer M, Garraux G, Gispert S, Auburger G, Vilariño-Güell C, Hadjigeorgiou GM, Hicks AA, Hattori N, Jeon BS, Jamrozik Z, Krygowska-Wajs A, Lesage S, Lill CM, Lin JJ, Lynch T, Lichtner P, Lang AE, Libioulle C, Murata M, Mok V, Jasinska-Myga B, Mellick GD, Morrison KE, Meitnger T, Zimprich A, Opala G, Pramstaller PP, Pichler I, Park SS, Quattrone A, Rogaeva E, Ross OA, Stefanis L, Stockton JD, Satake W, Silburn PA, Strom TM, Theuns J, Tan EK, Toda T, Tomiyama H, Uitti RJ, Van Broeckhoven C, Wirdefeldt K, Wszolek Z, Xiromerisiou G, Yomono HS, Yueh KC, Zhao Y, Gasser T, Maraganore D, Krüger R; GEOPD consortium.

J Med Genet. 2012 Nov;49(11):721-6. doi: 10.1136/jmedgenet-2012-101155. Erratum in: J Med Genet. 2013 Mar;50(3):202.

32.

Large-scale replication and heterogeneity in Parkinson disease genetic loci.

Sharma M, Ioannidis JP, Aasly JO, Annesi G, Brice A, Van Broeckhoven C, Bertram L, Bozi M, Crosiers D, Clarke C, Facheris M, Farrer M, Garraux G, Gispert S, Auburger G, Vilariño-Güell C, Hadjigeorgiou GM, Hicks AA, Hattori N, Jeon B, Lesage S, Lill CM, Lin JJ, Lynch T, Lichtner P, Lang AE, Mok V, Jasinska-Myga B, Mellick GD, Morrison KE, Opala G, Pramstaller PP, Pichler I, Park SS, Quattrone A, Rogaeva E, Ross OA, Stefanis L, Stockton JD, Satake W, Silburn PA, Theuns J, Tan EK, Toda T, Tomiyama H, Uitti RJ, Wirdefeldt K, Wszolek Z, Xiromerisiou G, Yueh KC, Zhao Y, Gasser T, Maraganore D, Krüger R; GEO-PD Consortium.

Neurology. 2012 Aug 14;79(7):659-67. doi: 10.1212/WNL.0b013e318264e353. Epub 2012 Jul 11.

33.

Genomic determinants of motor and cognitive outcomes in Parkinson's disease.

Chung SJ, Armasu SM, Biernacka JM, Anderson KJ, Lesnick TG, Rider DN, Cunningham JM, Eric Ahlskog J, Frigerio R, Maraganore DM.

Parkinsonism Relat Disord. 2012 Aug;18(7):881-6. doi: 10.1016/j.parkreldis.2012.04.025. Epub 2012 May 30.

34.

Mutations in CIZ1 cause adult onset primary cervical dystonia.

Xiao J, Uitti RJ, Zhao Y, Vemula SR, Perlmutter JS, Wszolek ZK, Maraganore DM, Auburger G, Leube B, Lehnhoff K, LeDoux MS.

Ann Neurol. 2012 Apr;71(4):458-69. doi: 10.1002/ana.23547. Epub 2012 Mar 23.

35.

Comprehensive research synopsis and systematic meta-analyses in Parkinson's disease genetics: The PDGene database.

Lill CM, Roehr JT, McQueen MB, Kavvoura FK, Bagade S, Schjeide BM, Schjeide LM, Meissner E, Zauft U, Allen NC, Liu T, Schilling M, Anderson KJ, Beecham G, Berg D, Biernacka JM, Brice A, DeStefano AL, Do CB, Eriksson N, Factor SA, Farrer MJ, Foroud T, Gasser T, Hamza T, Hardy JA, Heutink P, Hill-Burns EM, Klein C, Latourelle JC, Maraganore DM, Martin ER, Martinez M, Myers RH, Nalls MA, Pankratz N, Payami H, Satake W, Scott WK, Sharma M, Singleton AB, Stefansson K, Toda T, Tung JY, Vance J, Wood NW, Zabetian CP; 23andMe Genetic Epidemiology of Parkinson's Disease Consortium; International Parkinson's Disease Genomics Consortium; Parkinson's Disease GWAS Consortium; Wellcome Trust Case Control Consortium 2), Young P, Tanzi RE, Khoury MJ, Zipp F, Lehrach H, Ioannidis JP, Bertram L.

PLoS Genet. 2012;8(3):e1002548. doi: 10.1371/journal.pgen.1002548. Epub 2012 Mar 15.

36.

Translation initiator EIF4G1 mutations in familial Parkinson disease.

Chartier-Harlin MC, Dachsel JC, Vilariño-Güell C, Lincoln SJ, Leprêtre F, Hulihan MM, Kachergus J, Milnerwood AJ, Tapia L, Song MS, Le Rhun E, Mutez E, Larvor L, Duflot A, Vanbesien-Mailliot C, Kreisler A, Ross OA, Nishioka K, Soto-Ortolaza AI, Cobb SA, Melrose HL, Behrouz B, Keeling BH, Bacon JA, Hentati E, Williams L, Yanagiya A, Sonenberg N, Lockhart PJ, Zubair AC, Uitti RJ, Aasly JO, Krygowska-Wajs A, Opala G, Wszolek ZK, Frigerio R, Maraganore DM, Gosal D, Lynch T, Hutchinson M, Bentivoglio AR, Valente EM, Nichols WC, Pankratz N, Foroud T, Gibson RA, Hentati F, Dickson DW, Destée A, Farrer MJ.

Am J Hum Genet. 2011 Sep 9;89(3):398-406. doi: 10.1016/j.ajhg.2011.08.009.

37.

Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case-control study.

Ross OA, Soto-Ortolaza AI, Heckman MG, Aasly JO, Abahuni N, Annesi G, Bacon JA, Bardien S, Bozi M, Brice A, Brighina L, Van Broeckhoven C, Carr J, Chartier-Harlin MC, Dardiotis E, Dickson DW, Diehl NN, Elbaz A, Ferrarese C, Ferraris A, Fiske B, Gibson JM, Gibson R, Hadjigeorgiou GM, Hattori N, Ioannidis JP, Jasinska-Myga B, Jeon BS, Kim YJ, Klein C, Kruger R, Kyratzi E, Lesage S, Lin CH, Lynch T, Maraganore DM, Mellick GD, Mutez E, Nilsson C, Opala G, Park SS, Puschmann A, Quattrone A, Sharma M, Silburn PA, Sohn YH, Stefanis L, Tadic V, Theuns J, Tomiyama H, Uitti RJ, Valente EM, van de Loo S, Vassilatis DK, Vilariño-Güell C, White LR, Wirdefeldt K, Wszolek ZK, Wu RM, Farrer MJ; Genetic Epidemiology Of Parkinson's Disease (GEO-PD) Consortium.

Lancet Neurol. 2011 Oct;10(10):898-908. doi: 10.1016/S1474-4422(11)70175-2. Epub 2011 Aug 30. Erratum in: Lancet Neurol. 2011 Oct;10(10):870.

38.

Do interactions between SNCA, MAPT, and LRRK2 genes contribute to Parkinson's disease susceptibility?

Biernacka JM, Armasu SM, Cunningham JM, Ahlskog JE, Chung SJ, Maraganore DM.

Parkinsonism Relat Disord. 2011 Dec;17(10):730-6. doi: 10.1016/j.parkreldis.2011.07.001. Epub 2011 Aug 3.

39.

Role of sepiapterin reductase gene at the PARK3 locus in Parkinson's disease.

Sharma M, Maraganore DM, Ioannidis JP, Riess O, Aasly JO, Annesi G, Abahuni N, Bentivoglio AR, Brice A, Van Broeckhoven C, Chartier-Harlin MC, Destée A, Djarmati A, Elbaz A, Farrer M, Ferrarese C, Gibson JM, Gispert S, Hattori N, Jasinska-Myga B, Klein C, Lesage S, Lynch T, Lichtner P, Lambert JC, Lang AE, Mellick GD, De Nigris F, Opala G, Quattrone A, Riva C, Rogaeva E, Ross OA, Satake W, Silburn PA, Theuns J, Toda T, Tomiyama H, Uitti RJ, Wirdefeldt K, Wszolek Z, Gasser T, Krüger R; Genetic Epidemiology of Parkinson's Disease Consortium.

Neurobiol Aging. 2011 Nov;32(11):2108.e1-5. doi: 10.1016/j.neurobiolaging.2011.05.024. Epub 2011 Jul 22.

PMID:
21782285
40.

Rationale for therapeutic silencing of alpha-synuclein in Parkinson's disease.

Maraganore DM.

J Mov Disord. 2011 May;4(1):1-7. doi: 10.14802/jmd.11001. Epub 2011 Apr 30. Review.

41.

Variants in estrogen-related genes and risk of Parkinson's disease.

Chung SJ, Armasu SM, Biernacka JM, Lesnick TG, Rider DN, Cunningham JM, Maraganore DM.

Mov Disord. 2011 Jun;26(7):1234-42. doi: 10.1002/mds.23604. Epub 2011 Apr 5.

42.

Common variants in PARK loci and related genes and Parkinson's disease.

Chung SJ, Armasu SM, Biernacka JM, Lesnick TG, Rider DN, Lincoln SJ, Ortolaza AI, Farrer MJ, Cunningham JM, Rocca WA, Maraganore DM.

Mov Disord. 2011 Feb 1;26(2):280-8. doi: 10.1002/mds.23376. Epub 2010 Dec 13.

43.

Independent and joint effects of the MAPT and SNCA genes in Parkinson disease.

Elbaz A, Ross OA, Ioannidis JP, Soto-Ortolaza AI, Moisan F, Aasly J, Annesi G, Bozi M, Brighina L, Chartier-Harlin MC, Destée A, Ferrarese C, Ferraris A, Gibson JM, Gispert S, Hadjigeorgiou GM, Jasinska-Myga B, Klein C, Krüger R, Lambert JC, Lohmann K, van de Loo S, Loriot MA, Lynch T, Mellick GD, Mutez E, Nilsson C, Opala G, Puschmann A, Quattrone A, Sharma M, Silburn PA, Stefanis L, Uitti RJ, Valente EM, Vilariño-Güell C, Wirdefeldt K, Wszolek ZK, Xiromerisiou G, Maraganore DM, Farrer MJ; Genetic Epidemiology of Parkinson's Disease (GEO-PD) Consortium.

Ann Neurol. 2011 May;69(5):778-92. doi: 10.1002/ana.22321. Epub 2011 Mar 9.

44.

Anxious personality predicts an increased risk of Parkinson's disease.

Bower JH, Grossardt BR, Maraganore DM, Ahlskog JE, Colligan RC, Geda YE, Therneau TM, Rocca WA.

Mov Disord. 2010 Oct 15;25(13):2105-13. doi: 10.1002/mds.23230.

45.

Novelty seeking and introversion do not predict the long-term risk of Parkinson disease.

Arabia G, Grossardt BR, Colligan RC, Bower JH, Maraganore DM, Ahlskog JE, Geda YE, Rocca WA.

Neurology. 2010 Jul 27;75(4):349-57. doi: 10.1212/WNL.0b013e3181ea15fd.

46.

A large-scale genetic association study to evaluate the contribution of Omi/HtrA2 (PARK13) to Parkinson's disease.

Krüger R, Sharma M, Riess O, Gasser T, Van Broeckhoven C, Theuns J, Aasly J, Annesi G, Bentivoglio AR, Brice A, Djarmati A, Elbaz A, Farrer M, Ferrarese C, Gibson JM, Hadjigeorgiou GM, Hattori N, Ioannidis JP, Jasinska-Myga B, Klein C, Lambert JC, Lesage S, Lin JJ, Lynch T, Mellick GD, de Nigris F, Opala G, Prigione A, Quattrone A, Ross OA, Satake W, Silburn PA, Tan EK, Toda T, Tomiyama H, Wirdefeldt K, Wszolek Z, Xiromerisiou G, Maraganore DM; Genetic Epidemiology of Parkinson's disease consortium.

Neurobiol Aging. 2011 Mar;32(3):548.e9-18. doi: 10.1016/j.neurobiolaging.2009.11.021. Epub 2009 Dec 24.

47.

Medical records documentation of constipation preceding Parkinson disease: A case-control study.

Savica R, Carlin JM, Grossardt BR, Bower JH, Ahlskog JE, Maraganore DM, Bharucha AE, Rocca WA.

Neurology. 2009 Nov 24;73(21):1752-8. doi: 10.1212/WNL.0b013e3181c34af5.

48.

Anemia or low hemoglobin levels preceding Parkinson disease: a case-control study.

Savica R, Grossardt BR, Carlin JM, Icen M, Bower JH, Ahlskog JE, Maraganore DM, Steensma DP, Rocca WA.

Neurology. 2009 Oct 27;73(17):1381-7. doi: 10.1212/WNL.0b013e3181bd80c1.

49.

Comparison of risk factor profiles in incidental Lewy body disease and Parkinson disease.

Frigerio R, Fujishiro H, Maraganore DM, Klos KJ, DelleDonne A, Heckman MG, Crook JE, Josephs KA, Parisi JE, Boeve BF, Dickson DW, Ahlskog JE.

Arch Neurol. 2009 Sep;66(9):1114-9. doi: 10.1001/archneurol.2009.170.

50.

Incidental Lewy body disease: do some cases represent a preclinical stage of dementia with Lewy bodies?

Frigerio R, Fujishiro H, Ahn TB, Josephs KA, Maraganore DM, DelleDonne A, Parisi JE, Klos KJ, Boeve BF, Dickson DW, Ahlskog JE.

Neurobiol Aging. 2011 May;32(5):857-63. doi: 10.1016/j.neurobiolaging.2009.05.019. Epub 2009 Jun 26.

Supplemental Content

Loading ...
Support Center